Mr. Kaseta joined Liquidia in December 2020 as Chief Financial Officer and added the title of Chief Operating Officer in January 2024. Mr. Kaseta’s extensive background spans corporate finance, business strategy and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Therapeutics, a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension (PAH). Previously, Mr. Kaseta served as the Chief Financial Officer at Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) and spent eleven years at Sanofi in a variety of financial roles, culminating in the Chief Financial Officer at Sanofi SA for North America Global Services and the North America Pharmaceutical Region. In this role he managed a $10 billion business covering several product launches and more than 100 products across eight therapeutic areas. Mr. Kaseta holds a BBA in accounting from James Madison University, is a CPA (inactive) licensed in the state of New Jersey, and serves as a director of Alimera Sciences, Inc. (Nasdaq: ALIM) and Bryn Pharma.